Seizure Disorders Clinical Trials

To assess whether an investigational drug called ZX008 can reduce the number of seizures experienced by children and young adults who have Dravet Syndrome. Current effective treatment options for Dravet Syndrome are limited, making this research very important.

This study is being conducted to demonstrate that perampanel given as adjunctive anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS).

A prolonged seizure affects individuals of all ages, from the very young to the elderly. Status Epilepticus (SE) is a life-threatening condition in which the brain is in a state of persistent seizure. SE is defined as a seizure or recurrent seizures lasting longer than five minutes without stopping on ...

This research study will examine the safety and efficacy of Eslicarbazepine Acetate therapy at a dose of 1600 mg/day in subjects with partial epilepsy not well controlled on their current anti epileptic regimen. Patient Inclusion Criteria: 16 -70 years of age Documented diagnosis of epilepsy w/EEG done in prior 10 ...

This research study will examine the safety and efficacy of adding Eslicarbazepine Acetate to patients original anti epileptic regimin for those individuals whose seizure are not well controlled on their current therapy. It is a 2 part study with approximately 615 participants. Part I will follow a group with an ...

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit    Other Details:  https://clinicaltrials.gov/ct2/show/NCT03021018  

The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal ...

This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4- dose-titration treatment period to dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.  

A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures.  

This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.